文献速递炎症性肠病

钙调神经磷酸酶抑制剂联合维得利珠单抗治疗难治性炎症性肠病的安全性与疗效

Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-05-08

该研究收集了2014年5月20日至2015年3月30日开始维得利珠单抗治疗并在前12个月内联用钙调神经磷酸酶抑制剂的CD患者9例和UC患者11例,分析其临床活动度评分和炎症标志物。第14周时44%的CD患者和55%的UC患者达到无激素临床缓解,第52周时分别为33%和45%。作者认为联合治疗在长达52周随访中能有效且安全地诱导和维持临床缓解。

要点

  • 第14周时44%的CD患者和55%的UC患者达到无激素临床缓解。
  • 第52周时33%的CD患者和45%的UC患者处于无激素临床缓解。
  • 共16例患者(59%)完成了52周维得利珠单抗治疗,3例严重不良事件与钙调神经磷酸酶抑制剂相关。

核心结论

  • 维得利珠单抗与环孢素或他克莫司联合治疗在长达52周随访中能有效且安全地诱导和维持CD和UC患者的临床缓解。
  • 作者认为需要更大规模的研究来探讨钙调神经磷酸酶抑制剂在维得利珠单抗治疗患者中诱导缓解的能力。

研究设计与样本

  • 研究收集了2014年5月20日至2015年3月30日开始维得利珠单抗治疗并在治疗前12个月内联用钙调神经磷酸酶抑制剂(他克莫司或环孢素)的CD患者9例和UC患者11例的数据。
  • 在基线以及维得利珠单抗治疗第14周、第30周和第52周测量临床活动度评分和炎症标志物。
  • 临床缓解定义为Harvey-Bradshaw指数评分≤4或短临床结肠炎活动指数评分≤2;无激素临床缓解定义为不用皮质类固醇的临床缓解。

主要发现

  • 治疗第14周时,44%的CD患者和55%的UC患者达到无激素临床缓解。
  • 治疗52周后,33%的CD患者和45%的UC患者处于无激素临床缓解。
  • 7例患者在维得利珠单抗原发无应答后接受钙调神经磷酸酶抑制剂挽救治疗,其中2例UC患者中的1例和5例CD患者中的2例停用钙调神经磷酸酶抑制剂并在第52周达到无激素缓解。
  • 共16例患者(59%)接受了52周维得利珠单抗治疗。
  • 3例严重不良事件与钙调神经磷酸酶抑制剂相关。

关键数值与推荐

  • 临床缓解定义为Harvey-Bradshaw指数评分≤4或短临床结肠炎活动指数评分≤2。
  • 无激素临床缓解定义为无皮质类固醇的临床缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Little is known about the efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab for patients with Crohn's disease (CD) or ulcerative colitis (UC). We analyzed the outcomes of patients receiving vedolizumab along with calcineurin inhibitors. METHODS: We collected data on patients with CD (n = 9) or UC (n = 11) who began treatment with vedolizumab from May 20, 2014, through March 30, 2015, and received calcineurin inhibitors (tacrolimus or cyclosporin) during the first 12 months of vedolizumab therapy. Clinical activity scores and inflammatory markers were measured at baseline and at weeks 14, 30, and 52 of vedolizumab treatment. Clinical remission was defined as a Harvey-Bradshaw index score ≤4 or short clinical colitis activity index score ≤2; steroid-free clinical remission was defined as clinical remission without corticosteroids. RESULTS: By week 14 of treatment, 44% of the patients with CD and 55% of the patients with UC achieved steroid-free clinical remission; after 52 weeks of treatment, 33% of the patients with CD and 45% of the patients with UC were in steroid-free clinical remission. Seven patients received salvage therapy with a calcineurin inhibitor after primary nonresponse to vedolizumab-1 of the 2 patients with UC and 2 of 5 patients with CD stopped taking the calcineurin inhibitors and achieved steroid-free remission at week 52. In total, 16 patients (59%) received 52 weeks of treatment with vedolizumab. Three serious adverse events were associated with calcineurin inhibitors. CONCLUSIONS: Combination therapy of vedolizumab with either cyclosporin or tacrolimus is effective and safe at inducing and maintaining clinical remission in patients with CD and UC with up to 52 weeks of follow-up evaluation. Larger studies of the ability of calcineurin inhibitors to induce remission in patients on vedolizumab are warranted.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Christensen B, Gibson PR, Micic D, et al. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2018. PMID: 29751166. doi:10.1016/j.cgh.2018.04.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。